TherapeuticsMD (TXMD) Cash & Equivalents (2010 - 2026)

TherapeuticsMD (TXMD) has 17 years of Cash & Equivalents data on file, last reported at $8.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 46.54% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (up 46.54% YoY) and the FY2025 annual result came in at $7.5 million, up 47.91% from the prior year.
• Cash & Equivalents grew to $8.4 million in Q1 2026, from $7.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $49.3 million in Q4 2022 to a low of $4.3 million in Q4 2023.
• A 5-year average of $15.0 million and a median of $7.5 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 91.23% — and 2025, when it surged 47.91%.
• Tracing TXMD's Cash & Equivalents over 5 years: stood at $49.3 million in 2022, then sank by 91.23% to $4.3 million in 2023, then gained by 16.92% to $5.1 million in 2024, then surged by 47.91% to $7.5 million in 2025, then rose by 12.51% to $8.4 million in 2026.
• The last three Cash & Equivalents figures came in at $8.4 million (Q1 2026), $7.5 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.